Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM0306 Plus Lenalidomide in Relapsed/Refractory Follicular Lymphoma
NCT07355283Phase 3Not yet recruiting
- Sponsor
- ImmuneOnco
- Start
- Feb 2026
- Primary completion
- Jul 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing IMM0306 + Lenalidomide with Placebo + Lenalidomide (2 arms). Primary endpoints: Complete Remission Rate at 48 months and Progression-Free Survival at 48 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
IMM0306S
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07355283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355283.